Running a head-to-head comparison... reveals mechanism-specific effects
Running a head-to-head comparison... reveals mechanism-specific effects
Roles and dose notes are as recorded from the source below — each member’s own page holds its sourced dosing and evidence (the same rows the peptide pages render).
Single-receptor GLP-1 agonist
Semaglutide is a medicine that copies a natural body chemical called GLP-1. It belongs to a group of drugs people often call weight-loss or diabetes 'pens.' It is sold under names like Ozempic and Wegovy, plus newer versions made by other companies.
As recorded in this stack’s source: Matched purity standards
Dual-receptor GLP-1/GIP agonist
Tirzepatide is a medicine given as a weekly shot. It helps people with type 2 diabetes and obesity.
As recorded in this stack’s source: Matched purity standards
Triple-receptor GLP-1/GIP/Glucagon agonist
Retatrutide is a new weight-loss medicine that is still being tested. It is a shot given once a week.
As recorded in this stack’s source: Matched purity standards
["Validates research across the agonist spectrum","Reveals mechanism-specific effects"]
Extracted from a vendor source — see the original page ↗. Stacks like this are community- and vendor-reported combinations, not clinically established protocols. For research purposes only — not medical advice.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.